Latest Pharma and Biotech News
Pharmaceutical
4 April 2025 A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.
Today's issue
Refine Search
Biosimilars
South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma (CT-P47), a biosimilar referencing RoActemra (tocilizumab), which is marketed by Swiss pharma giant Roche. 25 February 2025
Pharmaceutical
After a significant increase in 2023, Danish regions' expenses for subsidized medicines fell by 4.3% in 2024. 24 February 2025
Pharmaceutical
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. 24 February 2025
Pharmaceutical
US CNS-focused biopharma firm Axsome Therapeutics today announced that the EMERGE Phase III trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint. 24 February 2025
Biotechnology
US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a hemophilia B gene therapy marketed as Beqvez in the USA and Durveqtix in Europe. 24 February 2025
Pharmaceutical
One of the USA’s largest compounders, Hims & Hers, has announced the acquisition of a peptide facility in California. 24 February 2025
Pharmaceutical
Mitsubishi Tanabe Pharma (MTPC) today announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for ND0612, an investigational treatment for motor fluctuations in Parkinson's disease (PD) on February 20. 24 February 2025
Pharmaceutical
Spanish dermatology company Almirall was trading 4% higher on Monday afternoon after presenting its full-year 2024 financial results. 24 February 2025
Biosimilars
Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, the medicine is commercially available to patients across the USA. 24 February 2025
Pharmaceutical
Earlier this month, the Norwegian government launched the cancer strategy Joint Efforts Against Cancer, with five national goals and 17 new ten-year goals, which set ambitions for the cancer area up to 2035. 24 February 2025
Pharmaceutical
Kelso Pharma, the British specialty pharma business backed by Apposite Capital, today announced the acquisition of the UK pharma business, Alturix Holdings Limited. Financial terms were not disclosed. 24 February 2025
Pharmaceutical
The US Food and Drug Administration (FDA) late Friday revealed it has approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. 24 February 2025
Pharmaceutical
Japanese drug major Shionogi announced that Jeil Pharmaceutical, its partner in South Korea, has obtained marketing approval from the domestic authorities for the gram-negative bacterial infection treatment Fetroja (cefiderocol). 24 February 2025
Pharmaceutical
US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir for HIV prevention. 24 February 2025
Pharmaceutical
New plans have been unveiled to make Britain’s science and technology links with the European Union (EU) stronger and deeper, following a fruitful visit to Brussels by the UK’s Science and Technology Secretary, to meet some of the new slate of European Commissioners. 23 February 2025
Biotechnology
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered into a collaboration with Stoke Therapeutics on the development of zorevunersen for Dravet syndrome. US firm Arcus BioSciences presented new data on its kidney cancer disease candidate casdatifan, which Gilead Sciences had an option to license, but at the last moment pulled out of the deal. On the M&A front, with the aim of expanding its China operations, the UK’s AstraZeneca struck a deal to acquire the China business unit of FibroGen, Also, struggling US biotech bluebird bio announced an agreement to be acquired by investment firms Carlyle and SK Capital, for just around $30 million upfront, a fraction of the $10 billion it was valued at its peak. 23 February 2025
Pharmaceutical
India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a rising cancer burden and demand for cutting-edge treatments. Leading the charge are big domestic pharma spearheading the launch of breakthrough oncology drugs. 23 February 2025
Pharmaceutical
The new US President has repealed an executive order from October 2023, signed by the Biden administration, that sought to establish rigorous safeguards for artificial intelligence (AI) development. 22 February 2025
Biotechnology
French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal antibody targeting TL1A, in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease (IBD). 22 February 2025
Pharmaceutical
The US Food and Drug Administration (FDA) said it has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is now resolved. 22 February 2025
All news
Pharmaceutical
al rule on April 4, that modernizes and improves Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost plan, and Programs of All-Inclusive Care for the Elderly (PACE) programs.
New Medicare proposals will not cover obesity drugs
April 4, 2025 5 April 2025
Pharmaceutical
A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced. 4 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Biotechnology
Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses as chairman. 4 April 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults living with immunoglobulin G4-related disease (IgG4-RD), the drug’s developer, Amgen announced yesterday. 4 April 2025
Biotechnology
US biotech MoonLake Immunotherapeutics has entered into an agreement with Hercules Capital for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake’s strategy and funding needs. 4 April 2025
Biotechnology
Struggling US genomic medicines company Sangamo Therapeutics has been offered a lifeline via a licensing deal with pharma major Eli Lilly, sending its share up 24% to $0.77. 4 April 2025
Biosimilars
An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary of Biocon. 4 April 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive condition that runs in families caused by a protein called transthyretin (TTR). 4 April 2025
Pharmaceutical
US biotech Aldeyra Therapeutics has received a Complete Response Letter from the US Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of its dry eye disease candidate reproxalap. 4 April 2025
Biotechnology
Swiss pharma giant Roche’s Genentech subsidiary has presented new data at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. 4 April 2025
Biotechnology
A new report from GlobalData has raised concerns over the effectiveness of mpox vaccines for people living with HIV. 4 April 2025
Biotechnology
UK pharma major AstraZeneca today reported extended approvals in Europe for two of its cancer drugs: Imfinzi (durvalumab) and Enhertu (trastuzumab deruxtecan). 4 April 2025
Biotechnology
US biotech Novavax is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April 1 target date to complete its review. 4 April 2025
Biotechnology
US regenerative cell therapy specialist Neurona Therapeutics has announced the successful completion of an upsized and oversubscribed $102 million financing. 4 April 2025
Pharmaceutical
US pharma major Eli Lilly’s brand value has surged by 108% since entering the weight loss market in 2023, according to a new report from Brand Finance. 3 April 2025
Biotechnology
US biotech BioMarin Pharmaceutical yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically-significant lowering in blood phenylalanine( Phe) levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone. 3 April 2025
Biotechnology
Sino-American biotech BeiGene today revealed it intends to discontinue its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. 3 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze